Clorox (NYSE:CLX – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 6.650-6.900 for the period, compared to the consensus estimate of 6.650. The company issued revenue guidance of $7.0 billion-$7.1 billion, compared to the consensus revenue estimate of $7.0 billion. Clorox also updated its FY25 guidance to $6.65-$6.90 EPS.
Clorox Stock Up 2.9 %
Shares of Clorox stock traded up $4.56 on Friday, reaching $163.11. 2,296,113 shares of the company were exchanged, compared to its average volume of 1,243,288. Clorox has a one year low of $121.76 and a one year high of $169.09. The company has a market capitalization of $20.20 billion, a price-to-earnings ratio of 56.83, a PEG ratio of 3.12 and a beta of 0.41. The company has a current ratio of 1.03, a quick ratio of 0.63 and a debt-to-equity ratio of 5.04. The company has a 50-day moving average of $161.48 and a 200 day moving average of $146.14.
Clorox (NYSE:CLX – Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. The business had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a return on equity of 292.08% and a net margin of 4.78%. The firm’s revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.49 EPS. On average, equities research analysts forecast that Clorox will post 6.64 earnings per share for the current year.
Clorox Announces Dividend
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on CLX. TD Cowen began coverage on Clorox in a report on Tuesday, July 23rd. They set a “sell” rating and a $122.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Citigroup upped their price objective on Clorox from $165.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, September 6th. BNP Paribas raised Clorox to a “strong sell” rating in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. upped their price objective on Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a report on Friday, October 11th. Six investment analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $150.29.
Read Our Latest Stock Report on CLX
Insider Activity
In related news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the sale, the executive vice president now directly owns 13,471 shares in the company, valued at $2,229,719.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.57% of the company’s stock.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Read More
- Five stocks we like better than Clorox
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Battle of the Retailers: Who Comes Out on Top?
- Short Selling: How to Short a Stock
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.